The company delivered 18 abstracts, with key highlights including long-term Phase 3 data on CAPLYTA for schizophrenia and new analyses of seltorexant in major depressive disorder with insomnia. These findings target persistent symptoms that many standard treatments fail to address.
Highlighting Breakthrough Data
- Oral presentations on CAPLYTA Phase 3 data demonstrated a reduced risk of relapse in schizophrenia.
- Phase 3 results for seltorexant examined its adjunctive benefits on mood, sleep, cognition, and metabolic health.
- Additional CAPLYTA analyses reviewed remission rates across different patient subgroups in major depressive disorder.
- SPRAVATO data from the SUSTAIN-1 study helped identify predictors of relapse in treatment-resistant depression.
- A HoPE LAI panel provided practical guidance on the use of long-acting injectables for patients and caregivers.
Real-World Impact on Patient Care
All data were generated from rigorous Phase 3 trials, including placebo-controlled relapse-prevention studies and adjunctive therapy evaluations. Post-hoc analyses further explored remission rates, cognition, and safety across diverse patient populations. The work reflects both strong clinical experience and transparent reporting standards.
These neuropsychiatry treatment innovations have the potential to lower long-term healthcare costs associated with relapse and repeated treatment cycling. By delivering better symptom control and improved sleep management, they could reduce hospital visits and meaningfully enhance daily functioning and quality of life for many patients.
Frequently Asked Questions
What do the new data mean for people with major depressive disorder and insomnia?
Seltorexant shows promise as an add-on therapy. It may simultaneously ease mood and sleep symptoms while limiting next-day sedation.
How does CAPLYTA help prevent relapse in schizophrenia?
Long-term Phase 3 results indicate significantly lower relapse rates, supporting steadier, more sustained symptom control over time.
Why focus on long-acting injectables for early schizophrenia care?
The HoPE LAI panel equips nurse practitioners and physician assistants with clear, practical talking points designed to improve adherence during the critical first years following diagnosis.
Overall, these updates strengthen the evidence base for targeted therapies and highlight promising future directions in precision neuropsychiatry.
